Company insider dossier

Agios Pharm insider intelligence

AGIO filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
25/100

Concentrated distribution

58/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
4 Aug 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 15 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 04 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Conviction25Concentrated distribution
Confidence58Developing
Named insiders15participating in the tape
Controlled events2directional common-share events
Acquisition value$0normalized amount
Disposal value$1.1Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

43.6538.8534.0529.2624.46 Disposal · 4 Aug 2026 · $914.4KAcquisition · 8 Jul 2026 · Not reportedAcquisition · 1 Jul 2026 · Not reportedDisposal · 1 Jul 2026 · $150.5KAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 18 Jun 2026 · Not reportedAcquisition · 13 Jun 2026 · Not reportedAcquisition · 13 Jun 2026 · Not reported
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
32.27 USD
One-week move
+7.5%
Four-week move
-21.7%
Fair-value gap
-4.2%
Trend signal
Active
Relative strength
-14.1

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
2
Net value
-$1.1M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
408 Jun
4615 Jun
022 Jun
329 Jun
206 Jul
013 Jul
020 Jul
027 Jul
103 Aug
010 Aug

Named participants

Insider conviction by person

BACKSTROM, JAY T.Director500 events
BALLAL, RAHUL D.Director500 events
BURNS, JAMES WILLIAMChief Legal Officer500 events
CAPELLO, JEFFREY DDirector500 events
FOSTER-CHEEK, KAYE IDirector500 events
FOUSE, JACQUALYN ADirector500 events
GOFF, BRIANDirector, Chief Executive Officer500 events
HO, MAYKINDirector500 events
JONES, CECILIAChief Financial Officer500 events
MILANOVA, TSVETAChief Commercial Officer500 events
OWEN, ADAMS CATHERINEDirector500 events
SCADDEN, DAVIDDirector500 events

Evidence quality

Security and transaction context

Common equity14
Equity compensation33
Options and derivatives9
Other securities0

Role architecture

Who is participating

Director40
Other executive12
CEO and chair2
Finance leadership2

Transaction evidence

Auditable AGIO filing ledger

Showing 1 to 30 of 56.

GHEUENS, SARAHChief Medical Officer
DisposalCommon equity
30000 sharesCommon stock
$914.4KDirectional evidence
BACKSTROM, JAY T.Director
DisposalEquity compensation
1447 sharesRestricted stock units
Not reportedContext evidence
BACKSTROM, JAY T.Director
AcquisitionCommon equity
1447 sharesCommon stock
Not reportedContext evidence
GHEUENS, SARAHChief Medical Officer
AcquisitionCommon equity
8375 sharesCommon stock
Not reportedContext evidence
GHEUENS, SARAHChief Medical Officer
DisposalEquity compensation
8375 sharesRestricted stock units
Not reportedContext evidence
GHEUENS, SARAHChief Medical Officer
DisposalCommon equity
4007 sharesCommon stock
$150.5KDirectional evidence
BACKSTROM, JAY T.Director
AcquisitionEquity compensation
2927 sharesRestricted stock units
Not reportedContext evidence
BACKSTROM, JAY T.Director
AcquisitionOptions and derivatives
14950 sharesStock options (right to buy)
Not reportedContext evidence
BALLAL, RAHUL D.Director
AcquisitionCommon equity
2816 sharesCommon stock
Not reportedContext evidence
BALLAL, RAHUL D.Director
AcquisitionEquity compensation
2927 sharesRestricted stock units
Not reportedContext evidence
BALLAL, RAHUL D.Director
DisposalEquity compensation
2816 sharesRestricted stock units
Not reportedContext evidence
BALLAL, RAHUL D.Director
AcquisitionOptions and derivatives
14950 sharesStock options (right to buy)
Not reportedContext evidence
BURNS, JAMES WILLIAMChief Legal Officer
AcquisitionEquity compensation
3000 sharesRestricted stock units
Not reportedContext evidence
BURNS, JAMES WILLIAMChief Legal Officer
DisposalEquity compensation
3000 sharesPerformance share units
Not reportedContext evidence
CAPELLO, JEFFREY DDirector
AcquisitionEquity compensation
2927 sharesRestricted stock units
Not reportedContext evidence
CAPELLO, JEFFREY DDirector
AcquisitionCommon equity
2816 sharesCommon stock
Not reportedContext evidence
CAPELLO, JEFFREY DDirector
AcquisitionOptions and derivatives
14950 sharesStock options (right to buy)
Not reportedContext evidence
CAPELLO, JEFFREY DDirector
DisposalEquity compensation
2816 sharesRestricted stock units
Not reportedContext evidence
FOSTER-CHEEK, KAYE IDirector
DisposalEquity compensation
2816 sharesRestricted stock units
Not reportedContext evidence
FOSTER-CHEEK, KAYE IDirector
AcquisitionCommon equity
2816 sharesCommon stock
Not reportedContext evidence
FOSTER-CHEEK, KAYE IDirector
AcquisitionOptions and derivatives
14950 sharesStock options (right to buy)
Not reportedContext evidence
FOSTER-CHEEK, KAYE IDirector
AcquisitionEquity compensation
2927 sharesRestricted stock units
Not reportedContext evidence
FOUSE, JACQUALYN ADirector
DisposalEquity compensation
2816 sharesRestricted stock units
Not reportedContext evidence
FOUSE, JACQUALYN ADirector
AcquisitionCommon equity
2816 sharesCommon stock
Not reportedContext evidence
FOUSE, JACQUALYN ADirector
AcquisitionOptions and derivatives
14950 sharesStock options (right to buy)
Not reportedContext evidence
FOUSE, JACQUALYN ADirector
AcquisitionEquity compensation
2927 sharesRestricted stock units
Not reportedContext evidence
GHEUENS, SARAHChief Medical Officer
DisposalEquity compensation
3000 sharesPerformance share units
Not reportedContext evidence
GHEUENS, SARAHChief Medical Officer
AcquisitionEquity compensation
3000 sharesRestricted stock units
Not reportedContext evidence
GOFF, BRIANDirector, Chief Executive Officer
AcquisitionEquity compensation
39000 sharesRestricted stock units
Not reportedContext evidence
GOFF, BRIANDirector, Chief Executive Officer
DisposalEquity compensation
39000 sharesPerformance share units
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context